MSc and MRes programmes still open to applications
5 August 2024
We're very pleased to be able to share the news that we're still accepting applications for postgraduate taught programmes here at UCL Biochemical Engineering for applicants who don't require a visa.
The following programmes are still accepting applications for applicants who don't require a visa:
- Biochemical Engineering MSc
A multidisciplinary programme at the interface of biology and engineering providing graduates with the skills necessary to design, develop and oversee the next generation of industrial bioprocesses - Manufacturing and Commercialisation of Stem Cell and Gene Therapies MSc
Developing the next generation of multidisciplinary engineers, scientists and business professionals to overcome the manufacturing, scientific and commercial challenges of advanced stem cell and gene therapy development. - Synthetic Biology MRes
This one-year MRes programme aims to train students in the fast-growing area of synthetic biology to design and build novel artificial biological systems.
Dr Rana Khalife, admissions tutor for the Manufacturing and Commercialisation of Stem Cell and Gene Therapies MSc said:
"UK residents interested in pursuing an MSc in cell and gene therapy at University College London (UCL) have until 30 August to submit their applications for the upcoming academic year. This innovative and industrially-relevant MSc, which is co-developed and co-delivered by industry experts, provides key skills, practical training and expertise to develop future generations of engineers, scientists and business professionals with the breadth and depth required to manufacture and deliver 21st-century medicines.
This one-year, full-time programme will provide you with the latest advances in the rapidly growing sector of advanced therapies and regenerative medicine, as well as provide an in-depth industry perspective, research experience with internationally renowned research groups and key transferable skills to catapult your career.
Apply now to secure your spot in shaping the future of cell and gene therapy at UCL."